About Allurion
Allurion is a company based in Wellesley (United States) founded in 2009. Allurion has raised $174.04 million across 19 funding rounds from investors including SVB, RTW Investments and Bridge Bank. The company has 137 employees as of December 31, 2024. Allurion operates in a competitive market with competitors including Apollo Endo, Sedivention, GT Metabolic Solutions, Spatz FGIA and IG Balloon, among others.
- Headquarter Wellesley, United States
- Employees 137 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allurion Technologies, Inc.
-
Annual Revenue
$32.11 M (USD)-39.94as on Dec 31, 2024
-
Net Profit
-$7.2 M (USD)91.48as on Dec 31, 2024
-
EBITDA
-$45.25 M (USD)42.22as on Dec 31, 2024
-
Total Equity Funding
$174.04 M (USD)
in 19 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Nov 14, 2025
-
Investors
SVB
& 9 more
-
Employee Count
137
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Allurion
Allurion is a publicly listed company on the NYSE with ticker symbol ALUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Allurion
Unlock access to complete
Unlock access to complete
Funding Insights of Allurion
Allurion has successfully raised a total of $174.04M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allurion
Allurion has secured backing from 10 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include SVB, RTW Investments and Bridge Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Investment and advisory services are provided for life sciences.
|
Locked | Locked | Locked | |
|
Early-stage VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Allurion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allurion
Investment portfolio details for Allurion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allurion
Detailed financials for Allurion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allurion Comparisons
Peer comparison for Allurion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allurion
Allurion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Apollo Endo, Sedivention, GT Metabolic Solutions, Spatz FGIA and IG Balloon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for obesity and GI disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of a minimally invasive cryo-ablation therapy for obesity. This outpatient procedure uses cryo-ablation technology to disrupt the gastric branches of the vagus nerve, permanently reducing hunger feelings. A medical device has been developed and successfully tested for safety and efficacy. The therapy aims to provide a long-term solution for weight loss, addressing a significant unmet medical need. The company is supported by several awards and investments.
|
|
| Locked | Locked | Locked |
Incision-less bariatric surgery technology is developed for gastric bypass.
|
|
| Locked | Locked | Locked |
Minimally invasive gastric balloon is developed for obesity satiety induction.
|
|
| Locked | Locked | Locked |
Offers updates on medical device designs and clinical trial outcomes.
|
Detailed competitors of Allurion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allurion
Complete news archive for Allurion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allurion
Allurion was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Allurion is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Allurion is a funded company, having raised a total of $174.04M across 19 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Allurion is 137.
Annual revenue of Allurion is $32.11M as on Dec 31, 2024.
Allurion Technologies was founded in 2009 in Wellesley, United States, focusing on medical devices in the weight management sector. The Elipse intragastric balloon is developed as a non-surgical option, swallowed via capsule and filled with liquid through a catheter. It remains in the stomach for around four months before emptying and passing naturally. The device is integrated with physician-supervised weight loss programs, avoiding endoscopy or anesthesia.
Allurion's top competitors include Apollo Endo, GT Metabolic Solutions and Sedivention.
Yes, Allurion is publicly traded on NYSE under the ticker symbol ALUR.
Allurion has 10 investors. Key investors include SVB, RTW Investments, Bridge Bank, Runway Growth Capital, and Novalis LifeSciences.
The ticker symbol of Allurion is ALUR on NYSE.